skip to content


Indivior asserts new patent against ANDA-filers

15 September 2017 07:24

Indivior's US subsidiary, Indivior Inc, has filed patent lawsuits against Dr Reddy's, Actavis, Par, Alvogen, Teva, and Mylan for infringement of US Patent No. 9,687,454 relating to their respective proposed generic versions of the company's SUBOXONE (buprenorphine and naloxone) Sublingual Film product.

These lawsuits allege that these companies infringe the '454 patent, which was issued on 27 Jun 2017, and is listed in the FDA's Orange Book.

The '454 patent relates to an oral film containing buprenorphine and naloxone.

Indivior has been involved in patent infringement litigation involving other, earlier issued patents covering SUBOXONE film with these same companies relating to their proposed generic products.

Story provided by

Related Company: INDV

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.